Beanlands R S, Bach D S, Raylman R, Armstrong W F, Wilson V, Montieth M, Moore C K, Bates E, Schwaiger M
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
J Am Coll Cardiol. 1993 Nov 1;22(5):1389-98. doi: 10.1016/0735-1097(93)90548-f.
The aim of this study was to use positron emission tomography (PET)-derived carbon (C)-11 acetate kinetics to determine the effects of dobutamine on oxidative metabolism and its effects on myocardial efficiency in a group of patients with dilated cardiomyopathy.
Dobutamine is known to improve myocardial function but may do so at the expense of myocardial oxygen consumption, which could be a potential deleterious effect. Carbon-11 acetate kinetics correlate with myocardial oxygen consumption as shown in animal models. Combining these scintigraphic measurements of oxygen consumption with estimates of cardiac work results in a work-metabolic index, which reflects cardiac efficiency.
Eight patients with nonischemic dilated cardiomyopathy underwent dynamic PET imaging, echocardiography and hemodynamic measurements. Seven of these patients were also studied while receiving dobutamine. Direct measurements of myocardial oxygen consumption using coronary sinus catheterization were obtained with eight of the PET studies to validate C-11 acetate in patients with cardiomyopathy.
The mean (+/- SD) C-11 clearance rate significantly increased with dobutamine from 0.105 +/- 0.027 to 0.155 +/- 0.023 min-1 (p = 0.001). Directly measured myocardial oxygen consumption had a linear relation to the mean C-11 clearance rate (r = 0.8, p = 0.018). Dobutamine was noted to significantly reduce systemic vascular resistance as well as the severity of mitral regurgitation. The work-metabolic index determined using hemodynamic variables and PET data increased from 2 +/- 0.7 x 10(4) to 2.6 +/- 0.6 x 10(4) (p = 0.04). Efficiency, estimated by employing the oxygen consumption to k2 relation, also increased from 13 +/- 4.5% to 16.9 +/- 6.4% (p = 0.04).
Despite an increase in myocardial oxygen consumption, dobutamine led to an increase in work-metabolic index in patients with dilated nonischemic cardiomyopathy. Dobutamine reduced systemic vascular resistance and mitral regurgitation, suggesting that in this group of patients, it had important vasodilatory action in addition to its inotropic effects. The use of the C-11 acetate PET for determining myocardial oxygen consumption and estimating efficiency could potentially complement existing clinical measures of ventricular performance and may allow improved and objective evaluation of therapy in patients with heart failure.
本研究旨在利用正电子发射断层扫描(PET)衍生的碳(C)-11 乙酸盐动力学,来确定多巴酚丁胺对一组扩张型心肌病患者氧化代谢的影响及其对心肌效率的影响。
已知多巴酚丁胺可改善心肌功能,但可能是以增加心肌氧耗为代价,这可能是一种潜在的有害作用。如在动物模型中所示,碳-11 乙酸盐动力学与心肌氧耗相关。将这些氧耗的闪烁扫描测量值与心脏做功估计值相结合,可得出一个反映心脏效率的做功-代谢指数。
8 例非缺血性扩张型心肌病患者接受了动态 PET 成像、超声心动图和血流动力学测量。其中 7 例患者在接受多巴酚丁胺治疗时也进行了研究。在 8 次 PET 研究中,通过冠状窦插管直接测量心肌氧耗,以验证心肌病患者中 C-11 乙酸盐的情况。
多巴酚丁胺治疗时,平均(±标准差)C-11 清除率显著增加,从 0.105±0.027 升至 0.155±0.023 min⁻¹(p = 0.001)。直接测量的心肌氧耗与平均 C-11 清除率呈线性关系(r = 0.8,p = 0.018)。多巴酚丁胺可显著降低体循环血管阻力以及二尖瓣反流的严重程度。利用血流动力学变量和 PET 数据确定的做功-代谢指数从 2±0.7×10⁴ 增至 2.6±0.6×10⁴(p = 0.04)。通过采用氧耗与 k2 关系估算的效率也从 13±4.5%增至 16.9±6.4%(p = 0.04)。
尽管心肌氧耗增加,但多巴酚丁胺使非缺血性扩张型心肌病患者的做功-代谢指数升高。多巴酚丁胺降低了体循环血管阻力和二尖瓣反流,表明在这组患者中,它除了具有正性肌力作用外,还具有重要的血管舒张作用。使用 C-11 乙酸盐 PET 来确定心肌氧耗和估算效率,可能会补充现有的心室功能临床测量方法,并可能改善对心力衰竭患者治疗的客观评估。